Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of $46.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda’s rating is based on several promising developments within Viridian Therapeutics’ pipeline, particularly the progress of VRDN-003. The completion of enrollment in the pivotal REVEAL program, which assesses the safety and efficacy of VRDN-003 in both active and chronic Thyroid Eye Disease (TED), is a significant milestone. The studies not only exceeded their enrollment targets but also have the potential to lead to a Biologics License Application (BLA) submission by the end of next year if the upcoming data is positive. This progress, combined with the drug’s advantageous properties, such as its formulation as a low-volume, self-administered autoinjector, positions VRDN-003 favorably in the TED market.
Additionally, the recent granting of a composition of matter patent for VRDN-003, valid until 2041, strengthens Viridian’s intellectual property portfolio. The anticipation of a BLA submission for veligrotug, another promising candidate, with a potential commercial launch in mid-2026, further supports the Buy rating. The Breakthrough Therapy Designation granted by the FDA underscores veligrotug’s rapid and significant clinical benefits, enhancing its differentiation from existing therapies. These factors collectively indicate a strong growth potential for Viridian Therapeutics, justifying the Buy recommendation.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.7% and a 53.33% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as VYNE Therapeutics, Dianthus Therapeutics, and Mineralys Therapeutics, Inc..
In another report released today, Wedbush also maintained a Buy rating on the stock with a $40.00 price target.